Literature DB >> 2719469

Treatment failure of norfloxacin against Campylobacter pylori and chronic gastritis in patients with nonulcerative dyspepsia.

J C Mertens1, W Dekker, E E Ligtvoet, P Blok.   

Abstract

Several reports have been published to show the in vitro susceptibility of Campylobacter pylori to different classes of antibiotics, including fluoroquinolones. The purpose of this study was to describe the clinical effect of norfloxacin on eradication of C. pylori in patients with gastritis. Endoscopy was performed in 38 patients with symptoms of nonulcerative dyspepsia. Of these, 20 patients had a C. pylori-positive culture. From this group, 17 patients were treated with norfloxacin for 1 month. After therapy, 15 patients still had positive cultures, and in 9 cases the strain was resistant to norfloxacin. These data, which confirm previous studies, support the concept that the in vitro activity of norfloxacin against C. pylori cannot be transposed to an in vivo effect.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2719469      PMCID: PMC171471          DOI: 10.1128/AAC.33.2.256

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.

Authors:  C A McNulty; J Dent; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

2.  Campylobacter pyloridis--a new factor in peptic ulcer disease?

Authors:  B J Rathbone; J I Wyatt; R V Heatley
Journal:  Gut       Date:  1986-06       Impact factor: 23.059

3.  Will antibacterial chemotherapy be efficacious for gastritis and peptic ulcer?

Authors:  C S Goodwin; J A Armstrong
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

4.  Campylobacter pylori and peptic ulcer disease.

Authors:  H J O'Connor; M F Dixon; J I Wyatt; A T Axon; E P Dewar; D Johnston
Journal:  Lancet       Date:  1987-09-12       Impact factor: 79.321

Review 5.  Dyspepsia: a dilemma for doctors?

Authors:  R V Heatley; B J Rathbone
Journal:  Lancet       Date:  1987-10-03       Impact factor: 79.321

6.  Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents.

Authors:  D L Shungu; D R Nalin; R H Gilman; H H Gadebusch; A T Cerami; C Gill; B Weissberger
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

7.  [Ofloxacin in the therapy of Campylobacter pylori-positive duodenal ulcer. A prospective controlled randomized study].

Authors:  E Bayerdörffer; G Kasper; T Pirlet; A Sommer; R Ottenjann
Journal:  Dtsch Med Wochenschr       Date:  1987-09-11       Impact factor: 0.628

8.  The histological diagnosis of chronic gastritis in fibreoptic gastroscope biopsy specimens.

Authors:  R Whitehead; S C Truelove; M W Gear
Journal:  J Clin Pathol       Date:  1972-01       Impact factor: 3.411

  8 in total
  8 in total

1.  Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors:  T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  In vitro selection of resistant Helicobacter pylori.

Authors:  C E Haas; D E Nix; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

3.  Role of metronidazole resistance in therapy of Helicobacter pylori infections.

Authors:  H Rautelin; K Seppälä; O V Renkonen; U Vainio; T U Kosunen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  In vitro and in vivo activities of tea catechins against Helicobacter pylori.

Authors:  K Mabe; M Yamada; I Oguni; T Takahashi
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 5.  Helicobacter pylori in gastroduodenal disease.

Authors:  R J Loffeld
Journal:  Pharm Weekbl Sci       Date:  1990-04-27

6.  Eradication of Helicobacter mustelae from the ferret stomach: an animal model of Helicobacter (Campylobacter) pylori chemotherapy.

Authors:  G Otto; J G Fox; P Y Wu; N S Taylor
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.

Authors:  M Nakao; M Tada; K Tsuchimori; M Uekata
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

8.  Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.

Authors:  K Nagata; H Satoh; T Iwahi; T Shimoyama; T Tamura
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.